Journal of Cancer Research and Immuno-Oncology
Open Access
ISSN: 2684-1266
ISSN: 2684-1266
Catherine Ronin
Aix-Marseille University, France
Scientific Tracks Abstracts: J Cancer Res Immunooncol
The number of antibody candidates to fight cancer is presently increasing as humanized, engineered and bispecific antibodies develop into a wide array of novel protein formats which are more than often challenging to produce. Glycan’s account for the most sophisticated weavings in nature and physiologically govern targeting of all antibodies to a large panel of receptors in immune cells, tumors as well as in pathogens. In antibodies more particularly, a sugar switch controls targeting to activating, inhibitory and lectin receptors on NK cells, macrophages and lymphocytes. Glycosylation is therefore a hot issue for the Biotech field, especially through its direct association with quality, safety and efficacy of antibody-based products. From lead identification to full scale production of bio therapeutics, regulators are now requesting deeper knowledge about both the process and products. Immunotherapies have essentially focused on bio potency which largely depends on antibody glycosylation, especially core focus, galactose and sialic acid. Product quality is most than often drastically altered because cell factories poorly adapt to high density culture and fail to deliver high titer production. Optimal glycoengineering is therefore needed to get better and safer products. Glycosylation is protein-, cell- and process specific. Glycan heterogeneity can thus be seen as a bar code for product quality to govern the overall production workflow. Customizable glycotests help to readily maximize antibody glycoprofile during cell line management and product development. Such glycomonitoring aims at making decision with confidence and without delay, accelerating development timeline to readily achieve better process consistency as well as higher product quality.
Catherine Ronin carried out a full academic career as Professor at Aix-Marseille University (France) and founded SiaMed’Xpress in 2010. She has published more than 75 scientific papers in reputed journals, written 32 patents and has been serving as VC/C at the European Research Agency over 12 years. She is currently evaluator at the French programs for Innovative Biotherapies..